Targeted in situ sequencing directly maps editing rates at single-cell resolution in postmortem tissues to visualize base and prime editor delivery.
Category: bioengineering
Genetic engineering reduces plant’s chromosome number without affecting its growth
Higher yields, greater resilience to climatic changes or diseases—the demands on crop plants are constantly growing. To address these challenges, researchers of Karlsruhe Institute of Technology (KIT) are developing new methods in genetic engineering.
In cooperation with other German and Czech researchers, they succeeded for the first time in leveraging the CRISPR/Cas molecular scissors for changing the number of chromosomes in the Arabidopsis thaliana model organism in a targeted way—without any adverse effects on plant growth. This discovery opens up new perspectives for plant breeding and agriculture. The results have been published in Science.
The CRISPR/Cas molecular scissors enabled the KIT researchers in recent years to alter not only genes, but also chromosomes. This way, it is possible to combine wanted traits or eliminate unwanted ones in plants in a targeted manner.
From artificial organs to advanced batteries: A breakthrough 3D-printable polymer
A new type of 3D-printable material that gets along with the body’s immune system, pioneered by a University of Virginia research team, could lead to safer medical technology for organ transplants and drug delivery systems. It could also improve battery technologies.
The breakthrough is the subject of a new article published in the journal Advanced Materials, based on work done by the University of Virginia’s Soft Biomatter Laboratory, led by Liheng Cai, an associate professor of materials science and engineering and chemical engineering. The paper’s first author is Baiqiang Huang, a Ph.D. student in the School of Engineering and Applied Science.
Their research shows a way to change the properties of polyethylene glycol to make stretchable networks. PEG, as it’s known, is a material already used in many biomedical technologies such as tissue engineering, but the way PEG networks are currently produced—created in water by crosslinking linear PEG polymers, with the water removed afterward—leaves a brittle, crystallized structure that can’t stretch without losing its integrity.
Brain organoid pioneers fear inflated claims about biocomputing could backfire
For the brain organoids in Lena Smirnova’s lab at Johns Hopkins University, there comes a time in their short lives when they must graduate from the cozy bath of the bioreactor, leave the warm, salty broth behind, and be plopped onto a silicon chip laced with microelectrodes. From there, these tiny white spheres of human tissue can simultaneously send and receive electrical signals that, once decoded by a computer, will show how the cells inside them are communicating with each other as they respond to their new environments.
More and more, it looks like these miniature lab-grown brain models are able to do things that resemble the biological building blocks of learning and memory. That’s what Smirnova and her colleagues reported earlier this year. It was a step toward establishing something she and her husband and collaborator, Thomas Hartung, are calling “organoid intelligence.”
Tead More
Another would be to leverage those functions to build biocomputers — organoid-machine hybrids that do the work of the systems powering today’s AI boom, but without all the environmental carnage. The idea is to harness some fraction of the human brain’s stunning information-processing superefficiencies in place of building more water-sucking, electricity-hogging, supercomputing data centers.
Despite widespread skepticism, it’s an idea that’s started to gain some traction. Both the National Science Foundation and DARPA have invested millions of dollars in organoid-based biocomputing in recent years. And there are a handful of companies claiming to have built cell-based systems already capable of some form of intelligence. But to the scientists who first forged the field of brain organoids to study psychiatric and neurodevelopmental disorders and find new ways to treat them, this has all come as a rather unwelcome development.
At a meeting last week at the Asilomar conference center in California, researchers, ethicists, and legal experts gathered to discuss the ethical and social issues surrounding human neural organoids, which fall outside of existing regulatory structures for research on humans or animals. Much of the conversation circled around how and where the field might set limits for itself, which often came back to the question of how to tell when lab-cultured cellular constructs have started to develop sentience, consciousness, or other higher-order properties widely regarded as carrying moral weight.
Next-generation microbiome medicine may transform Parkinson’s treatment
The age-old advice to “trust your gut” could soon take on new meaning for people diagnosed with Parkinson’s disease, thanks to a creative feat of bioengineering by researchers in the University of Georgia’s College of Veterinary Medicine.
Anumantha Kanthasamy, professor and director of the Isakson Center for Neurological Disease Research (ICNDR) leads a multidisciplinary research team including Gregory Phillips, Piyush Padhi, and other scientists that has engineered a groundbreaking living medicine, a beneficial probiotic designed to deliver levodopa steadily from the gut to the brain of Parkinson’s patients.
In a paper published in the journal Cell Host & Microbe, Kanthasamy’s team details how they engineered and tested the probiotic bacterium Escherichia coli Nissle 1917 as a drug-delivery system that continuously produces and delivers the gold-standard Parkinson’s drug, which is converted to dopamine in the brain. The E. coli Nissle strain was chosen for its century-long record of safely treating gastrointestinal disorders in humans.
CRISPR breakthrough reverses chemotherapy resistance in lung cancer
In a major step forward for cancer care, researchers at ChristianaCare’s Gene Editing Institute have shown that disabling the NRF2 gene with CRISPR technology can reverse chemotherapy resistance in lung cancer. The approach restores drug sensitivity and slows tumor growth. The findings are published in the journal Molecular Therapy Oncology.
This breakthrough stems from more than a decade of research by the Gene Editing Institute into the NRF2 gene, a known driver of treatment resistance. The results were consistent across multiple in vitro studies using human lung cancer cell lines and in vivo animal models.
“We’ve seen compelling evidence at every stage of research,” said Kelly Banas, Ph.D., lead author of the study and associate director of research at the Gene Editing Institute. “It’s a strong foundation for taking the next step toward clinical trials.”
Diverse particles form identical geometric patterns when confined, model reveals
Particles as different as soap bubbles and ball bearings can be made to arrange themselves in exactly the same way, according to a new study that could unlock the creation of brand new materials—including those with promising biomedical applications.
The international study, involving Professor Simon Cox from Aberystwyth University, reveals how diverse particles self-organize into identical geometric patterns when confined. The work is published in the journal Physical Review E.
The discovery could help scientists design advanced materials for medical use—including in smart drug delivery systems and targeted therapies. It could also offer valuable insights for tissue engineering, where understanding how biological cells arrange themselves in tight spaces is essential for developing effective scaffolds and regenerative treatments.
Scientists Tricked Bacteria Into Making the Octopus’s Secret Camouflage Pigment
The team’s solution hinges on a clever trick of synthetic biology called “growth-coupled biosynthesis.” Most biomanufacturing efforts try to coax microbes into making a product as a side gig. But the bacteria often resist, directing their resources toward survival instead.
This research flipped the incentive. The scientists engineered a strain of Pseudomonas putida that could only survive if it produced xanthommatin—or more precisely, if it also made a byproduct called formic acid in the process. This formate, a one-carbon molecule, fuels critical metabolic cycles. No formate, no growth.